DEFAL

This brand name is authorized in Nigeria. It is also authorized in Ecuador.

Active ingredients

The drug DEFAL contains one active pharmaceutical ingredient (API):

1	Deflazacort UNII KR5YZ6AE4B - DEFLAZACORT
	Deflazacort is a glucocorticoid. Its anti-inflammatory and immunosuppressive effects are used in treating a variety of diseases and are comparable to other anti-inflammatory steroids.
	Read more about Deflazacort

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-1473	Tablet	Defal 6 Tablets TAB 6 mg		21/12/2020
C4-1474	Tablet	Defal 30 Tablets TAB 30 mg		21/12/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H02AB13	Deflazacort	H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN → H02AB Glucocorticoids
Discover more medicines within H02AB13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	361120712, 366400613, 367590813
NG	Registered Drug Product Database	C4-1473, C4-1474